Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Dere R, Yi JH, Lei C, Saad OM, Huang C, Li Y, Baudys J, Kaur S.

Bioanalysis. 2013 May;5(9):1025-40. doi: 10.4155/bio.13.72.

PMID:
23641694
2.

A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.

Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE.

AAPS J. 2014 Sep;16(5):994-1008. doi: 10.1208/s12248-014-9618-3. Epub 2014 Jun 11.

3.

Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Carrasco-Triguero M, Yi JH, Dere R, Qiu ZJ, Lei C, Li Y, Mahood C, Wang B, Leipold D, Poon KA, Kaur S.

Bioanalysis. 2013 May;5(9):1007-23. doi: 10.4155/bio.13.64.

PMID:
23641693
4.

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.

Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A.

Cancer Chemother Pharmacol. 2012 May;69(5):1229-40. doi: 10.1007/s00280-011-1817-3. Epub 2012 Jan 20.

5.

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.

Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM.

J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):557-71. doi: 10.1007/s10928-013-9329-x. Epub 2013 Aug 10.

PMID:
23933716
6.

Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.

Sapra P, Betts A, Boni J.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):541-55. doi: 10.1586/17512433.2013.827405. Epub 2013 Aug 26. Review.

PMID:
23978126
7.

Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.

Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C, Raab H, Xie D, Akutagawa J, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A.

Bioconjug Chem. 2008 Aug;19(8):1673-83. doi: 10.1021/bc800059t. Epub 2008 Jul 19.

PMID:
18637680
8.

Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.

Wada R, Erickson HK, Lewis Phillips GD, Provenzano CA, Leipold DD, Mai E, Johnson H, Tibbitts J.

Cancer Chemother Pharmacol. 2014 Nov;74(5):969-80. doi: 10.1007/s00280-014-2561-2. Epub 2014 Sep 4.

PMID:
25186956
9.

Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.

Marcoux J, Champion T, Colas O, Wagner-Rousset E, Corvaïa N, Van Dorsselaer A, Beck A, Cianférani S.

Protein Sci. 2015 Aug;24(8):1210-23. doi: 10.1002/pro.2666. Epub 2015 Mar 31.

10.

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.

Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, Pinkas J, Tibbitts J.

Mol Cancer Ther. 2012 May;11(5):1133-42. doi: 10.1158/1535-7163.MCT-11-0727. Epub 2012 Mar 9.

11.

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O'Donohue A, Darwish M, Yip V, Liu L, Leipold DD, Su D, Wu E, Spencer SD, Shen BQ, Xu K, Kozak KR, Raab H, Vandlen R, Lewis Phillips GD, Scheller RH, Polakis P, Sliwkowski MX, Flygare JA, Junutula JR.

J Med Chem. 2014 Oct 9;57(19):7890-9. doi: 10.1021/jm500552c. Epub 2014 Sep 18.

PMID:
25191794
12.

A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates.

Fleming MS, Zhang W, Lambert JM, Amphlett G.

Anal Biochem. 2005 May 15;340(2):272-8.

PMID:
15840500
13.

Target-mediated drug disposition model and its approximations for antibody-drug conjugates.

Gibiansky L, Gibiansky E.

J Pharmacokinet Pharmacodyn. 2014 Feb;41(1):35-47. doi: 10.1007/s10928-013-9344-y. Epub 2013 Dec 11.

PMID:
24322877
14.

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.

Roberts SA, Andrews PA, Blanset D, Flagella KM, Gorovits B, Lynch CM, Martin PL, Kramer-Stickland K, Thibault S, Warner G.

Regul Toxicol Pharmacol. 2013 Dec;67(3):382-91. doi: 10.1016/j.yrtph.2013.08.017. Epub 2013 Sep 5.

PMID:
24012707
15.

Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.

Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M.

Bioanalysis. 2013 Jan;5(2):201-26. doi: 10.4155/bio.12.299. Erratum in: Bioanalysis. 2013 Mar;5(6):741. Bioanalysis. 2013 Nov;5(21):2734.

PMID:
23330562
16.

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.

Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin JY.

Cancer Chemother Pharmacol. 2014 Aug;74(2):399-410. doi: 10.1007/s00280-014-2500-2. Epub 2014 Jun 18.

17.

Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate.

Kim MT, Chen Y, Marhoul J, Jacobson F.

Bioconjug Chem. 2014 Jul 16;25(7):1223-32. doi: 10.1021/bc5000109. Epub 2014 Jun 24.

PMID:
24873191
18.

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.

LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX.

Clin Cancer Res. 2011 Oct 15;17(20):6437-47. doi: 10.1158/1078-0432.CCR-11-0762. Review.

19.

Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine.

Sandra K, Vanhoenacker G, Vandenheede I, Steenbeke M, Joseph M, Sandra P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 1;1032:119-30. doi: 10.1016/j.jchromb.2016.04.040. Epub 2016 Apr 27.

PMID:
27160547
20.

Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.

Sauerborn M, van Dongen W.

BioDrugs. 2014 Aug;28(4):383-91. doi: 10.1007/s40259-014-0096-z. Review.

PMID:
24842227

Supplemental Content

Support Center